None of the information presented should be construed as an offer to sell or buy any particular security. ADVM stock forecast Our latest prediction for Adverum Biotechnologies, Inc.'s stock price was made on the Dec. 23, 2019 when the stock price was at 11.06$.. In the short term (2weeks), ADVM's stock price should underperform the market by -4.91%.During that period the price should oscillate between … Start NOW! AIStockFinder will not accept liability for any loss or damage, including without limitation to, any loss of profit, which may arise directly or indirectly from use of or reliance on such information.On its last earning announcement, the company reported a loss of -1.09$ per share. Following the latest results, Adverum Biotechnologies's five analysts are now forecasting revenues of US$568.0k in 2020. It focuses on treatment of wet age-related macular degeneration, alpha-1 antitrypsin deficiency, hereditary angioedema, friedreich's ataxia, severe allergy, color vision deficiency, and juvenile x-linked retinoschisis. As always, use your best judgment when investing.Secure Your Limited Time Only Trial Access None out of 10 have rated it as a Hold, with 9 advising it as a Buy. Adverum Biotechnologies, Inc. (NASDAQ:ADVM) has a beta value of 2.11 and has seen 919,456 shares traded in the last trading session. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. Further, owners, employees, agents or representatives of Financhill are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Over the past 30 days, the shares of Adverum Biotechnologies, Inc. (NASDAQ:ADVM) have changed -6.91%. Will Adverum Biotechnologies Inc NASDAQ:ADVM meet your expectations? Adverum Biotechnologies, Inc Stock Price Forecast, "ADVM" Predictons for2020 View real-time stock prices and stock quotes for a full financial overview. Morningstar: © 2019 Morningstar, Inc. All Rights Reserved. Used by many of the world's smartest investorsFor Dividend Stocks, Blue Chip Stocks, Most Active Stocks, Most Shorted Stocks, Cheap Stocks, Stocks on Sale, and much moreScan for stocks set to soar and crash based on powerful seasonal trends plus view the stock with the most powerful seasonal trend this weekGet new stock ideas every day delivered to your inbox based on income, stock ratings, seasonal trends, best value, and moreOver the next 52 weeks, Adverum Biotechnologies Inc has on average historically risen by 42.8% based on the past 5 years of stock performance.Seasonal Stock Forecasts, Stock Valuations, Predictive Stock Analytics and see the #1 stock for the next 7 daysGain full access to our most highly screened value stocks that even Buffett may approveFinanchill is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Year-to-date, Adverum Biotechnologies, Inc. shares have moved 53.12%, while the 5-day performance has seen it change 1.5%.
Adverum Biotechnologies Inc. analyst estimates by MarketWatch. Growth estimates for the current quarter are -21.7% and -16% for the next quarter. All Rights Reserved.REDWOOD CITY, Calif., July 21, 2020 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare ...At the moment the company doesn't generate any revenue.Zacks Investment Research downgraded shares of Adverum Biotechnologies (NASDAQ:ADVM) from a hold rating to a sell rating in a research note published on Tuesday, Zacks.com reports.